122 related articles for article (PubMed ID: 7561096)
1. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.
Yang G; Hellström KE; Mizuno MT; Chen L
J Immunol; 1995 Oct; 155(8):3897-903. PubMed ID: 7561096
[TBL] [Abstract][Full Text] [Related]
2. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.
Gajewski TF; Renauld JC; Van Pel A; Boon T
J Immunol; 1995 Jun; 154(11):5637-48. PubMed ID: 7538528
[TBL] [Abstract][Full Text] [Related]
3. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
4. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
5. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
Yang G; Mizuno MT; Hellström KE; Chen L
J Immunol; 1997 Jan; 158(2):851-8. PubMed ID: 8993003
[TBL] [Abstract][Full Text] [Related]
6. Requirements for CD28-dependent T cell-mediated cytotoxicity.
Azuma M; Cayabyab M; Phillips JH; Lanier LL
J Immunol; 1993 Mar; 150(6):2091-101. PubMed ID: 8383716
[TBL] [Abstract][Full Text] [Related]
7. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
8. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H
Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141
[TBL] [Abstract][Full Text] [Related]
9. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors.
Liu B; Podack ER; Allison JP; Malek TR
J Immunol; 1996 Feb; 156(3):1117-25. PubMed ID: 8557987
[TBL] [Abstract][Full Text] [Related]
10. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 can replace CD28-dependent T-cell costimulation during nonspecific cytotoxic T lymphocyte induction by anti-CD3 antibody.
Makrigiannis AP; Musgrave BL; Haeryfar SM; Hoskin DW
J Leukoc Biol; 2001 Jan; 69(1):113-22. PubMed ID: 11200055
[TBL] [Abstract][Full Text] [Related]
12. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
13. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
Prell RA; Kerkvliet NI
J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
[TBL] [Abstract][Full Text] [Related]
14. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
15. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
[TBL] [Abstract][Full Text] [Related]
16. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
Schirmbeck R; Böhm W; Reimann J
J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
[TBL] [Abstract][Full Text] [Related]
18. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
19. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
[TBL] [Abstract][Full Text] [Related]
20. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
